The Hygeia Group, comprising three hospitals in Athens, Greece, joins Clinerion’s hospital network, and expands Clinerion’s Patient Network Explorer footprint in Europe. The Hygeia Group comprises three hospitals:
The Hygeia Hospital is the only hospital in Greece with a Joint Commission International (JCI) Gold Seal accreditation for quality and safety in healthcare. The group currently conducts above 80 clinical trials per year. Joining Clinerion’s Patient Network Explorer platform will bring more innovative treatments to the patients of the Hygeia Group’s hospitals and clinics, and give their physicians more options in treating their patients. The group will also gain more exposure to global clinical trials run by international pharmaceutical companies and contract research organizations. Drug developers working on innovative treatments will now benefit from access to these new geographies and clinics with strong therapeutic focus. “The strong oncology orientation of our hospitals along with the high-quality oncology staff provide a great opportunity to all stakeholders to enhance clinical trials with novel agents and combinations for our patients’ benefit,” says Mr. Andreas Kartapanis, CEO of the Hygeia Group. “The Hygeia Group has state-of-the-art infrastructure and equipment, and a roster of expert clinicians,” says Ian Rentsch, CEO of Clinerion. “This will be a great benefit to pharma companies and CROs looking to accelerate their drug trials in Greece.”
About Clinerion
Clinerion enables early patient access to innovative treatments through real-patient data solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Network Explorer accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-driven protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website:
www.clinerion.com
Clinerion’s Patient Network Explorer:
www.clinerion.com/index/OverviewOurSolutions/Clineriontechnologysolution
For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.